On Monday, Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), added 0.87% and closed at $29.06 in the last trading session. The last trading range of the stock ranges between $27.60 and $29.27. ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, recently declared its unaudited financial results for the third quarter ended September 30, 2016.
“We are very happy with the launch and are gratified by the positive feedback we have received from physicians, patients, and caregivers on NUPLAZID (pimavanserin),” said Steve Davis, ACADIA’s President and Chief Executive Officer. “We saw solid month-over-month prescription growth, stated raised payor coverage, and continued to expand awareness of NUPLAZID among movement disorder specialists, neurologists, and psychiatrists.”
News Corp (NASDAQ:NWSA), jumped 0.41% and closed at $12.17 in the last trading session. The last trading range of the stock ranges between $11.98 and $12.32. The company’s Market capitalization is $7.22 Billion with the total Outstanding Shares of 381.71 million. News Corporation (“News Corp” or the “Company”) (NWS) (NWSA) (NWS.AX) (NWSLV.AX) recently stated financial results for the three months ended September 30, 2016.
Commenting on the results, Chief Executive Robert Thomson said:
“News Corp made real progress as it continued to drive higher digital revenues and position the Company for long-term growth. While the quarter presented some obvious challenges, particularly in print advertising and the weakness of the Pound Sterling, our revenues were relatively stable, underscoring the strength and scale of our portfolio and shift to digital.
Our Digital Real Estate Services segment posted another strong quarter with an 18% year-over-year revenue increase and is on a clear path to reshape the character of News Corp. At Realtor.com®, we generated solid revenue growth even as we retooled our product offerings. We expect that momentum to accelerate this year and to contribute meaningfully to EBITDA.